High-Level Disinfectants & Terminal Sterilization Services Market: as the White House's two-year NESHAP compliance exemption removes near-term ethylene oxide facility closure risk, contract sterilizers are redirecting the capital that regulatory compliance would have absorbed toward biologics and cell and gene therapy capacity instead, so the exemption is reshaping investment priorities even though it did not change the underlying regulatory destination.

The global high-level disinfectants and terminal sterilization services market size was USD 7.28 Billion in 2025 and is expected to register a revenue CAGR of 5.0% during the forecast period.Market revenue growth is driven by the growing prevalence of healthcare-associated infections requiring stringent infection control protocols, expanding volumes of flexible endoscopy procedures requiring high-level disinfection between procedures, increasing adoption of heat-sensitive minimally invasive and robotic surgical instruments requiring low-temperature sterilization, and expanding pharmaceutical biologics and cell and gene therapy manufacturing requiring aseptic sterilization validation.STERIS reported approximately USD 5.9 Billion in total revenue, with its Applied Sterilization Technologies segment disclosing 9% contract-sterilization revenue growth in fiscal year 2024, citing biologics customers as a prime growth driver, and Healthcare segment operating margins reaching 25.1%.Fortive Corporation completed the acquisition of Advanced Sterilization Products from Ethicon Inc., a Johnson and Johnson subsidiary, for approximately USD 2.7 Billion, gaining the STERRAD low-temperature hydrogen peroxide system and EVOTECH and ENDOCLENS endoscope reprocessing platforms.Sixteen cell and gene therapies received US FDA approval in 2024, each requiring highly controlled aseptic fill-finish operations that drive demand for pharmaceutical aseptic sterilization and terminal sterilization validation services.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way regulatory relief on one compliance obligation frees capital that contract sterilizers redirect toward the fastest-growing customer segment rather than simply banking the savings.Once a contract sterilizer's ethylene oxide facility compliance deadline is pushed back, the capital expenditure that would have gone toward emissions control retrofits becomes available for expanding biologics and cell and gene therapy sterilization capacity instead, so the same regulatory relief that reduces near-term compliance risk also accelerates investment in the market's highest-margin growth segment.As a result, demand and revenue share are concentrating around contract sterilizers with both the EO compliance runway to avoid near-term facility disruption and active capital investment in biologics-focused sterilization and validation capacity, and the forecast reflects this dual capability as more decisive to near-term growth than raw sterilization volume alone.For instance, on July 17, 2025, the White House issued a Clean Air Act proclamation providing sterilization facilities with a two-year exemption from the EPA's revised NESHAP ethylene oxide emissions standards, giving contract sterilizers including Sotera Health's Sterigenics, STERIS, and BD additional time to install new control technology while continuing to redirect capital toward biologics-driven capacity expansion.These are some of the key factors driving revenue growth of the market.

Because occupational glutaraldehyde and ortho-phthalaldehyde exposure at hospital endoscopy reprocessing suites raises documented health concerns, this is driving substitution toward automated closed-system HLD platforms that reduce direct staff chemical exposure.

EO sterilization regulatory pressure is a second constraint, since EPA NESHAP compliance requirements continue to increase compliance capital cost for medical device manufacturers using contract EO sterilization, even accounting for the current compliance exemption.

Single-use device reprocessing competition is a third constraint, as reprocessing of single-use devices at hospitals represents a competing alternative to terminal sterilization that reduces device procurement cost at the expense of reprocessing validation complexity.

These factors substantially limit high-level disinfectants and terminal sterilization services market growth over the forecast period.

The clearest driver of demand is the expansion of contract sterilization revenue into pharmaceutical biologics and advanced therapy manufacturing. A contract sterilizer only captures this higher-margin biologics revenue if it has already built the aseptic validation and technology-neutral service capability biologics manufacturers require, and STERIS's AST segment, spanning gamma irradiation, EO processing, electron beam, X-ray, and laboratory testing, offers exactly that breadth. STERIS disclosed 9% contract-sterilization revenue growth in its AST segment in fiscal year 2024, with AST segment operating margins reaching 45.3% in Q3 fiscal year 2024, confirming that pharmaceutical and biologics customers generate the highest-margin growth within STERIS's portfolio. Sixteen cell and gene therapies received US FDA approval in 2024, each requiring highly controlled aseptic fill-finish operations that demand increased investment in tunnel sterilizers, hydrogen peroxide generators, and outsourced contract terminal sterilization and validation services. The effect on the market is that contract sterilization is bifurcating into a lower-margin traditional medical device business and a higher-margin biologics and advanced therapy business, with the latter increasingly determining which sterilizers capture above-market growth. These are some of the key factors driving revenue growth of the market.

The second driver is the structural shift toward heat-sensitive robotic and minimally invasive surgical instruments that cannot tolerate conventional steam sterilization. A hospital sterile processing department only adopts low-temperature sterilization at scale if its surgical instrument mix genuinely requires it, and the growing presence of robotic endowrist instrument shafts, articulating tip devices, and polymer laparoscopic components across more than 15% of US general surgery cases creates exactly that requirement. OECD data confirms hip and knee replacements among OECD members increased 4.2% per year between 2019 and 2024, introducing a steadily growing volume of robotic and MIS-compatible polymer instruments into hospital sterile processing workflows. STERIS introduced the Reliance EPS endoscope processing device for high-level disinfection in GI suites, while Getinge launched its next-generation Aquadis Endo 110 automated endoscope reprocessor in June 2026, increasing processing throughput by up to 36% compared to previous models. The effect on the market is that low-temperature sterilization and automated endoscope reprocessing capacity investment is becoming a structural requirement for hospital sterile processing departments, not a discretionary upgrade. These are some of the key factors driving revenue growth of the market.

“Getinge's Aquadis Endo 110 automated endoscope reprocessor increases processing throughput by up to 36% compared to previous models, addressing rising endoscopy procedure volumes that are straining hospital sterile processing department capacity.”

However, the high-level disinfectants and terminal sterilization services market faces severe adoption constraints from occupational chemical exposure risk, EO sterilization regulatory pressure, and single-use device reprocessing competition.

Because occupational glutaraldehyde and ortho-phthalaldehyde exposure at hospital endoscope reprocessing areas raises documented health concerns, this drives substitution toward automated closed-system HLD platforms that limit direct staff chemical contact.

EO sterilization regulatory pressure is a second constraint, as the EPA's NESHAP ethylene oxide emissions standards, even with the current two-year compliance exemption, will eventually require significant facility capital investment across the contract sterilization industry.

Single-use device reprocessing competition is a third constraint, since reprocessing of single-use devices at hospitals through FDA-registered reprocessors represents a competing alternative to terminal sterilization that reduces device procurement cost at the expense of reprocessing validation complexity.

These factors substantially limit high-level disinfectants and terminal sterilization services market growth over the forecast period.

Based on product type, the global high-level disinfectants and terminal sterilization services market is segmented into high-level chemical disinfectants, automated endoscope reprocessing systems, low-temperature sterilization systems, contract terminal sterilization services, and laboratory testing and validation services. High-level chemical disinfectants account for the largest revenue share at approximately 28% of 2025 market revenue. High-level chemical disinfectants including ortho-phthalaldehyde, glutaraldehyde-based formulations, and stabilised hydrogen peroxide liquid solutions play an essential role in flexible endoscope reprocessing between procedures at hospital GI suites, bronchoscopy units, and ambulatory surgical centres. Laboratory testing and sterilization validation services are expected to register the fastest revenue growth rate over the forecast period, driven by biologics pharmaceutical customers requiring comprehensive sterility assurance validation.

Based on end-use, the global high-level disinfectants and terminal sterilization services market is segmented into hospitals and acute care facilities, medical device manufacturers, pharmaceutical and biotechnology, and ambulatory surgical centres and GI endoscopy suites. Hospitals account for the largest revenue share through high-level endoscope disinfection, instrument sterilization, and infection prevention product procurement. Medical device manufacturer contract terminal sterilization is the second-largest end-use category, and pharmaceutical and biotech is the fastest-growing, driven by 16 US FDA cell and gene therapy approvals in 2024 and an expanding global biologics pipeline.

Based on regional analysis, the high-level disinfectants and terminal sterilization services market in North America accounted for the largest revenue share in 2025 at approximately 44% of global revenue. STERIS's approximately USD 5.9 Billion total revenue anchors North American market scale, and the FDA's November 2024 guidance on Transitional Enforcement Policy for EO Sterilization Facility Changes for Class III Devices confirms ongoing US regulatory attention to EO sterilization compliance. The July 2025 White House proclamation granting a two-year NESHAP compliance exemption directly affects the pace of facility capital investment across the North American contract sterilization industry.

The market in Europe is expected to register a steady revenue growth rate in the global high-level disinfectants and terminal sterilization services market over the forecast period.

Germany, France, the United Kingdom, and the Netherlands represent the four largest national high-level disinfection and sterilization services markets within Europe. EU Medical Device Regulation requirements for sterility assurance and reprocessing validation create sustained laboratory testing and validation services demand at European medical device manufacturers, while European CDMOs serving the biologics and advanced therapy medicinal product market drive growing contract aseptic sterilization demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global high-level disinfectants and terminal sterilization services market over the forecast period.

China, Japan, South Korea, Singapore, and India represent the five largest national high-level disinfection and sterilization markets within the region. Rising endoscopy procedure volumes and expanding hospital infrastructure investment across urban China and India are driving growing demand for automated endoscope reprocessing and high-level chemical disinfectant procurement, leaving substantial structural room for capacity growth relative to the already-mature North American market.

Latin America and Middle East and Africa markets are expected to register moderate revenue growth rates in the global high-level disinfectants and terminal sterilization services market over the forecast period.

Brazil and Mexico represent the two largest national high-level disinfection and sterilization services markets in Latin America, with growing hospital infrastructure investment supporting demand for infection control and sterilization capacity. Saudi Arabia and the UAE represent the primary GCC markets, with the Saudi Vision 2030 healthcare investment programme supporting new hospital construction and associated infection control and sterile processing infrastructure procurement.